These results indicated that CREB3L1 could function as a promising predictor for the sensitivity of several anti-cancer agents, such as cabozantinib, lenvatinib, zoledronate, dasatinib, and dabrafenib, which have been commonly applied in clinical cancer management. This evidence concerns the gene CREB3L1 and cancer.